Ad
DMPI - DelMar Pharmaceuticals Stock Trading
About | DelMar Pharmaceuticals (NASDAQ:DMPI)
DelMar Pharmaceuticals, Inc. is a clinical and commercial stage drug development company with a focus on the treatment of cancer.
Quote | DelMar Pharmaceuticals (NASDAQ:DMPI)
| Last: | $1.34 |
|---|---|
| Change Percent: | 7.2% |
| Open: | $1.22 |
| Close: | $1.34 |
| High: | $1.35 |
| Low: | $1.17 |
| Volume: | 1,321,048 |
| Last Trade Date Time: | 08/19/2020 04:58:56 pm |
News | DelMar Pharmaceuticals (NASDAQ:DMPI)
-
DelMar Pharmaceuticals ( DMPI +6.9% ) announces direct offering of 19,587 convertible preferred shares for the gross proceeds of ~$19.6M. That makes the offering priced at-the-market on $1,000 per share. More news on: DelMar Pharmaceuticals, Inc., , Stocks on the move, Healthcar...
-
SAN DIEGO , Aug. 18, 2020 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" or the "Company") announced today that it has entered into definitive agreements with investors providing for the sale and issuance of up to 19,587 shares of its Series C Convert...
Message Board Posts | DelMar Pharmaceuticals (NASDAQ:DMPI)
| Subject | By | Source | When |
|---|---|---|---|
| No posts yet. | |||
News, Short Squeeze, Breakout and More Instantly...
DelMar Pharmaceuticals Company Name:
DMPI Stock Symbol:
NASDAQ Market:
Ad
-
SAN DIEGO , Aug. 18, 2020 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" or the "Company") announced today that it has entered into definitive agreements with investors providing for the sale and issuance of up to 19,587 shares of its Series C Convert...
-
SAN DIEGO , Aug. 17, 2020 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" or the "Company") announced today that all proposals related to the proposed merger between DelMar and Adgero were approved by DelMar's stockholders at a special meeting held on August 14...
-
SAN DIEGO , July 17, 2020 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies announced today that it will be conducting a conference call to discuss...